Fox Chase Surgeon Robert G. Uzzo, MD, FACS, Recognized for Teaching the Next Generation of Urologic Surgeons

PHILADELPHIA, PA (May 20, 2014)—A nationally recognized leader in urologic oncology, Robert G. Uzzo, MD, FACS, understands the value of sharing his knowledge with the next generation. This week, Dr. Uzzo received the prestigious 2014 American Urologic Association’s (AUA) Residents Committee Teaching Award at the organization’s 2014 Annual Meeting in Orlando, FL. Dr. Uzzo is the Chair of the Department of Surgery at Fox Chase Cancer Center, and holds the G. Willing “Wing” Pepper Chair in Cancer Research.

The AUA Residents Committee Teaching Award is presented annually to recognize an outstanding urology educator or program director who has dedicated a portion of his/her career to teaching residents. This award also serves to recognize an individual who influences residents to pursue a career in academic medicine.

"Mentorship that trainees receive from Dr. Uzzo is colossal. The man is not only a true master at his trade, but also a tremendous mentor and teacher,” says Alexander Kutikov, MD, FACS, an attending surgeon at Fox Chase who trained under Dr. Uzzo. “Indeed, he is a role model like no other. All who have trained under him, with no exception, look up to him not only for his abilities as a surgeon, as a physician, and as an administrator and leader, but also for his unfailing capacity to remain a humble and superb human being. "

A fellow of the American College of Surgeons, Dr. Uzzo specializes in the treatment of kidney, prostate, testicular, and bladder cancers and procedures for urinary diversion. He is skilled in minimally invasive procedures, including pure laparoscopic and robotic surgery.  He is also the national urology principle investigator for the Eastern Cooperative Oncology Group (ECOG) trial to evaluate targeted therapies for kidney cancer, and is the co-chair of the genitourinary early management committee at ECOG.

Dr. Uzzo’s honors include the American Association of Cancer Research’s 1999 Yong Investigator Award. At the Cleveland Clinic Foundation, he was a fellow in urologic oncology and renal transplantation and renovascular surgery, as well as an American Foundation for Urologic Diseases scholar.

He is an active member of the American Urologic Association, American Association for Cancer Research, Society for Basic Urologic Research and the Society of Urologic Oncology. Dr. Uzzo has lectured extensively nationally and internationally on topics in urologic oncology and has published more than 200 chapters, manuscripts, and abstracts on various aspects of genitourinary malignances.

Dr. Uzzo is certified by the American Board of Urology. He received his MD from Cornell University Medical School and completed residencies at New York Hospital-Cornell University Medical Center and Memorial Sloan-Kettering Cancer Center.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427